Considerations For Migrating A Drug Product Presentation From Vial To Pre-Filled Syringe

Source: Pfizer CentreOne

By Martin Gonzalez, Ph.D., Sr. Manager Formulation and Process Development, Pfizer CentreOne


There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organizations (CDMO) to support the conversion of an existing product presentation into a different final container type. More specifically, providing options for moving a drug product from a vial into a pre-filled syringe (PFS).

There are many reasons why a drug developer may be interested in converting a drug product currently provided in a vial form into a PFS. It is sometimes driven by quality requirements to preserve product safety or potency. However, more often than not, the desire to create more patient-centric administration formats and to extend patents are underpinning the move.

In this article, Martin Gonzalez, Ph.D., Sr. Manager Formulation and Process Development at Pfizer CentreOne, discusses some of the most relevant engineering activities that are necessary to successfully transfer a product from vial into a PFS presentation.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development